Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Change in Accured Expenses (2022 - 2025)

Historic Change in Accured Expenses for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $5.0 million.

  • Taysha Gene Therapies' Change in Accured Expenses rose 107009.35% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year increase of 20499.44%. This contributed to the annual value of -$1.4 million for FY2024, which is 7736.18% up from last year.
  • Latest data reveals that Taysha Gene Therapies reported Change in Accured Expenses of $5.0 million as of Q3 2025, which was up 107009.35% from $732000.0 recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Change in Accured Expenses ranged from a high of $5.0 million in Q3 2025 and a low of -$7.7 million during Q2 2022
  • Over the past 4 years, Taysha Gene Therapies' median Change in Accured Expenses value was -$747000.0 (recorded in 2022), while the average stood at -$893733.3.
  • As far as peak fluctuations go, Taysha Gene Therapies' Change in Accured Expenses crashed by 245304.35% in 2023, and later soared by 107009.35% in 2025.
  • Taysha Gene Therapies' Change in Accured Expenses (Quarter) stood at -$747000.0 in 2022, then crashed by 170.01% to -$2.0 million in 2023, then soared by 105.26% to $106000.0 in 2024, then surged by 4624.53% to $5.0 million in 2025.
  • Its Change in Accured Expenses stands at $5.0 million for Q3 2025, versus $732000.0 for Q2 2025 and -$2.1 million for Q1 2025.